Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01857193
First received: May 16, 2013
Last updated: September 5, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2017
  Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)